BTN3A1

BTN3A1

BTN3A1 Informations sur la molécule

Molecule Name
Butyrophilin subfamily 3 member A1
Alias de la molécule
BTN3A1,CD277,BTF5
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
BTF5,BTN3A1,CD_antigen,BTN3.1,BT3.1,DJ45P21.3 (Butyrophilin, Subfamily 3, Member A1),Butyrophilin, Subfamily 3, Member A1,CD277 Antigen
Contexte de la molécule
Butyrophilin subfamily 3 member A1 (BTN3A1) is also known as CD277 and BTF5, which belongs to the immunoglobulin superfamily and contains one B30.2/SPRY domain and two Ig-like V-type (immunoglobulin-like) domains. BTN3A1 plays a role in T-cell activation and in the adaptive immune response. Also, BTN3A1 regulates the proliferation of activated T-cells and the release of cytokines and IFNG by activated T-cells. Furthermore, BTN3A1 mediates the response of T-cells toward infected and transformed cells that are characterized by high levels of phosphorylated metabolites, such as isopentenyl pyrophosphate.

BTN3A1 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
ICT-01(Imcheck Therapeutics)ICT-01Phase 2 ClinicalImCheck Therapeutics SAS
Hematologic Neoplasms; Lymphoma; Neoplasms; Solid tumours
Details